LONG-TERM ELAGOLIX + ADD-BACK THERAPY IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN FOR 48 MONTHS + 12 MONTH POST-TREATMENT FOLLOW-UP: A SAFETY UPDATE ON BONE MINERAL DENSITY DATA OF A PHASE 3 STUDY

This Phase 3 study updated bone mineral density data for elagolix plus add-back therapy in women with endometriosis-associated pain over 48 months of treatment and 12 months of follow-up.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works